US Cases / Year
~81,000
Approximately 81,800 new cases of kidney cancer diagnosed annually in the US, with RCC accounting for ~90% of all kidney cancers.[1]
What Is It
Definition, mechanism, and the clinical reality of this diagnosis at end of life. What the hospice team needs to understand on day one.
Clear Cell Predominance
~75%
Clear cell RCC is the most common histologic subtype and the most responsive to IO/TKI therapy. Subtype determines treatment and trajectory.[2]
Paraneoplastic Prevalence
20–40%
Up to 40% of RCC patients have at least one paraneoplastic syndrome — clinical problems caused by tumor-secreted substances, not tumor bulk.[3]
Metastatic 5-Year Survival
~16%
Overall metastatic 5-year survival ~16%, but modern IO/TKI combinations have dramatically improved this — median OS now 3–4 years in favorable-risk disease.[4]
Renal cell carcinoma (RCC) is a malignancy arising from the renal tubular epithelium of the kidney. It is the most common type of kidney cancer in adults, representing approximately 90% of all renal malignancies. RCC is a uniquely heterogeneous disease — encompassing clear cell, papillary, chromophobe, collecting duct, and medullary subtypes — each with distinct molecular biology, treatment response, and trajectory. The arrival of immunotherapy-based combinations (pembrolizumab + axitinib, nivolumab + cabozantinib, nivolumab + ipilimumab) has transformed metastatic RCC from a uniformly lethal diagnosis into one where durable complete responses occur in 8–12% of patients and median overall survival now exceeds 3 years in favorable-risk disease.[4][5]
This transformation creates a paradox for hospice. RCC patients may arrive with metastatic disease that has been managed for years — through multiple lines of VEGF-targeted therapy, immunotherapy combinations, and surgical metastasectomy — and may still have biologically active treatment options. Others arrive with rapidly progressive sarcomatoid disease, IMDC poor-risk classification, and a prognosis measured in weeks. The hospice clinician must understand both ends of this spectrum, because the disease that "always has one more option" and the disease that kills within months are the same diagnosis.[6]
Two features define the clinical reality of RCC at end of life. First, hemorrhage risk: RCC is among the most hypervascular tumors in oncology, and catastrophic bleeding from tumor erosion into major vessels, from the nephrectomy bed, or from vascular bone metastases is a documented clinical event that requires advance preparation. Second, paraneoplastic syndromes: up to 40% of patients have tumor-mediated clinical problems — hypercalcemia, polycythemia, paraneoplastic fever, hypertension — that create symptoms in organs far from the kidney and confound clinical assessment if not recognized.[3]
🧭 Clinical framing
RCC is unlike any other cancer in hospice for two reasons. First, it has the longest and most unpredictable trajectory — patients enrolled with weeks-to-live can stabilize unexpectedly on immunotherapy, while others with apparently stable disease can hemorrhage catastrophically without warning. Second, up to 40% of patients have paraneoplastic syndromes — clinical problems caused by tumor-secreted substances, not by tumor bulk — that create symptoms in organs far from the kidney. You cannot manage this disease without understanding both. When symptoms don't fit the metastatic pattern, think paraneoplastic. When the prognosis doesn't fit the imaging, think RCC.
"RCC will humble you. I've had patients enrolled with a two-week prognosis who were still on service eight months later, and patients with 'stable' disease who bled out from a bone met nobody flagged. This is the one cancer where your prognosis is wrong more often than it's right. And when a patient spikes a fever of 103 with no infection — and you're about to call for antibiotics — stop. It's probably the tumor. Know this disease before you walk in the door, or it will teach you the hard way."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Diagnostic Workup
- CT or MRI abdomen/pelvis with contrast: Gold standard — characteristic arterial enhancement pattern. Incidental discovery on imaging is how most RCC is now found; the classic symptomatic triad of flank pain, hematuria, and palpable mass presents in only ~10% of cases at diagnosis.[7]
- CT chest: Standard metastatic staging — lungs are the most common site of distant spread
- Bone scan or PET/CT: If bone metastases suspected based on symptoms (pain, elevated alkaline phosphatase) or imaging findings
- Brain MRI: If neurological symptoms present — RCC has a known propensity for brain metastases, particularly in clear cell histology[8]
- CT-guided core biopsy: Increasingly important for histologic subtype confirmation — subtype now directly determines therapy selection (clear cell vs non-clear cell pathways diverge completely)[2]
- IMDC Risk Score: International Metastatic RCC Database Consortium — the critical prognostic tool. Favorable (0 risk factors), Intermediate (1–2), Poor (≥3). Factors: anemia, hypercalcemia, time from diagnosis to treatment <1 year, KPS <80%, thrombocytosis (platelets >ULN), neutrophilia (neutrophils >ULN).[9]
Histologic Subtypes
- Clear cell (75%): Most common. Most responsive to VEGF-TKI and IO therapy. VHL gene inactivation drives angiogenesis.[2]
- Papillary type 1 and type 2 (15%): MET-driven. Type 2 is far more aggressive than type 1. Less responsive to standard IO/TKI.
- Chromophobe (5%): Often indolent. Best prognosis among subtypes when localized.
- Collecting duct (<1%): Extremely aggressive. Treated more like urothelial carcinoma. Median survival <1 year.
- Medullary RCC (<1%): Occurs almost exclusively in young Black Americans with sickle cell trait. Median survival ~5 months regardless of treatment.[10]
- Sarcomatoid differentiation (any subtype): Not a subtype but a dedifferentiation pattern. Poor prognosis regardless of underlying histology. IO has modestly improved outcomes.[11]
What to Look for in Hospice Records
- IMDC risk category: Favorable vs intermediate vs poor — this single classification defines trajectory and treatment expectations. Poor-risk patients have median OS 5–10 months; favorable-risk on modern IO may exceed 4 years.[9]
- Histologic subtype: Clear cell vs non-clear cell — determines which therapies were effective and what side effect profiles to expect
- Prior nephrectomy: Radical vs partial — remaining renal function determines drug clearance for every medication you prescribe. Single kidney patients require dose adjustments for renally-cleared drugs.
- Sarcomatoid component percentage: >50% sarcomatoid = very poor prognosis regardless of other factors
- Prior IO agents and duration of response: Pembrolizumab, nivolumab, ipilimumab — IO-related immune toxicities persist long after discontinuation. Know which agent, when it was stopped, and why.[12]
- Prior TKI agents: Sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib — TKI side effect profiles (hypertension, hand-foot syndrome, diarrhea, hepatotoxicity, hypothyroidism) inform symptom management even after discontinuation
- Bone met locations and load: Weight-bearing bone involvement determines fracture risk and mobility restrictions. Spinal cord compression risk from vertebral mets requires urgent assessment.[13]
- Brain met status: Managed with SRS vs WBRT vs untreated — determines neurological trajectory and steroid requirements
💡 For families
Most of the testing and diagnosis work has already been completed before hospice enrollment. Your loved one's medical team has already identified the type of kidney cancer, where it has spread, and which treatments have been tried. The hospice team uses this information to anticipate what symptoms to manage and how to keep your loved one comfortable. The focus now is entirely on comfort — no more scans, no more staging, no more waiting for results.
Causes & Risk Factors
Modifiable and hereditary risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"
Modifiable Risk Factors
- Tobacco smoking: 2x increased risk — most important modifiable factor. Accounts for ~20% of RCC cases. Risk decreases after cessation but never fully returns to baseline.[14]
- Obesity: BMI >30 — clear dose-response relationship; 30–70% increased risk. Most significant preventable risk factor in non-smokers. Mechanism involves chronic inflammation and altered sex hormone metabolism.[14]
- Hypertension: 2x increased risk — independent of antihypertensive treatment. One of the most consistent associations in RCC epidemiology.[14]
- Occupational exposure: Trichloroethylene (dry cleaning, degreasing) — IARC Group 1 carcinogen for kidney cancer. Asbestos and cadmium exposure also implicated.[15]
Hereditary & Non-Modifiable
- Chronic kidney disease and dialysis: 3–4x increased risk. Acquired cystic kidney disease on long-term dialysis is a recognized pathway.[14]
- Von Hippel-Lindau disease (VHL mutation): Germline. Clear cell RCC, hemangioblastomas, pheochromocytoma. 70% lifetime RCC risk.[16]
- Hereditary papillary RCC (MET mutation): Multiple bilateral papillary type 1 tumors. Autosomal dominant.
- Birt-Hogg-Dubé syndrome (FLCN mutation): Chromophobe and hybrid oncocytic RCC, pulmonary cysts, fibrofolliculomas.[16]
- Hereditary leiomyomatosis and RCC (FH mutation): Highly aggressive papillary type 2 RCC. Fumarate hydratase deficiency.
- Tuberous sclerosis (TSC1/TSC2): Angiomyolipoma and RCC.
❤️ For families: "Why did this happen?"
Kidney cancer usually develops from a combination of factors — some controllable, some not. Smoking, obesity, and high blood pressure increase the risk, but many patients have none of these. Some families carry gene changes that make kidney cancer more likely. This is not something your loved one caused or could have prevented. If there is a family history of kidney cancer or related conditions, the hospice team or your primary care doctor can discuss whether genetic testing might be appropriate for other family members.
⚕ Clinician note: Genetic counseling & disparities
Germline testing: VHL, FLCN, FH, MET, TSC1/2 — germline testing is appropriate even at hospice enrollment if not previously done. Implications for surviving family members are significant: VHL carries a 70% lifetime RCC risk, and early surveillance in carriers saves lives.[16]
Racial disparities: Black Americans have higher incidence of RCC than white Americans. Medullary RCC — an extremely aggressive subtype — occurs almost exclusively in young Black Americans with sickle cell trait and has a median survival of 5 months regardless of treatment. This represents one of the most severe cancer disparities in the US. Hispanic Americans also have modestly higher incidence. Access to nephrectomy, to clinical trials, and to immunotherapy combinations differs significantly by race and geography.[10][17]
Treatments & Procedures
What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.
The treatment landscape for metastatic RCC has been transformed by immunotherapy. Patients arriving on hospice may have received multiple lines of IO/TKI therapy over years, undergone cytoreductive nephrectomy, had metastasectomy of lung or brain lesions, and accumulated cumulative toxicities from VEGF-targeted agents and immune checkpoint inhibitors. Understanding this treatment history is essential for anticipating complications and interpreting the patient's current clinical picture.[4]
Surgery
- Radical nephrectomy: Standard for localized and selected metastatic disease. Cytoreductive nephrectomy in metastatic RCC is now more selective post-CARMENA trial — not routinely performed in IMDC poor-risk patients.[18]
- Partial nephrectomy: Nephron-sparing for smaller tumors. Remaining kidney function post-nephrectomy is relevant for drug clearance of every medication.
- Metastasectomy: Lung, adrenal, brain metastases in selected patients with solitary or oligometastatic disease. RCC is one of the few cancers where metastasectomy can achieve long-term disease-free survival.[19]
First-Line Systemic Therapy (Metastatic)
- Pembrolizumab + axitinib (KEYNOTE-426): Median OS not reached in favorable/intermediate-risk. Standard first-line for clear cell RCC.[4]
- Nivolumab + cabozantinib (CheckMate 9ER): Median OS ~37 months. Strong PFS benefit across all IMDC risk groups.[5]
- Nivolumab + ipilimumab (CheckMate 214): Favored in intermediate/poor-risk disease. Durable complete responses in ~10% of patients. Higher immune toxicity rate with dual IO.[6]
Second-Line & Beyond
- Cabozantinib: Specific activity in bone-dominant and hepatic metastatic RCC beyond other TKIs. METEOR trial.[20]
- Nivolumab monotherapy: If not used first-line. CheckMate 025 established second-line IO.
- Lenvatinib + everolimus: Third-line option after IO and TKI progression
- TKIs: Sunitinib, pazopanib — older first-line agents now largely replaced by IO combinations but patients may arrive with years of prior TKI exposure
- Belzutifan: Oral HIF-2α inhibitor for VHL-disease associated RCC. Highly targeted, good tolerability.[21]
Palliative Procedures
- Bone-modifying agents: Denosumab or zoledronic acid for bone mets — fracture prevention is comfort care. Denosumab preferred in renal impairment.[22]
- SRS for brain mets: RCC brain mets are radioresistant to conventional fractionation but respond to SRS. Know if done and when.[23]
- Palliative radiation: Single fraction 8 Gy for painful bone mets. Also for hemorrhage control from primary or metastatic sites.[24]
- Renal artery embolization: Selective tumor embolization for hemorrhage control — hospice-compatible comfort intervention.[25]
- Kyphoplasty/vertebroplasty: For painful vertebral compression fractures from lytic bone mets
- IPC (indwelling pleural catheter): For malignant pleural effusion if present
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.
RCC is one of the few cancers where the question of continuing disease-directed therapy at hospice enrollment is not rhetorical. Immunotherapy can produce durable complete responses. TKI therapy can maintain disease stability for years. The data supporting IO/TKI combinations in favorable and intermediate-risk disease is among the strongest in oncology. The conversation is not about giving up or holding on — it is about reading the clinical picture correctly.[4][5]
- 01IMDC favorable or intermediate risk with ECOG 0–1: Combination IO/TKI (pembrolizumab + axitinib, nivolumab + cabozantinib) offers median OS of 3–4+ years. A meaningful fraction of patients achieve durable complete responses. Treatment continuation is evidence-supported.[4]
- 02Clear cell histology with ECOG 0–2: Most responsive to IO-based combinations. Sunitinib or pazopanib as alternative if IO not tolerated. IO monotherapy (nivolumab) in second-line post-TKI remains effective in ECOG 0–2.
- 03Cabozantinib in bone-dominant or hepatic metastatic RCC: Specific activity in these sites beyond other TKIs. Worth discussing when bone or liver burden drives clinical picture.[20]
- 04Belzutifan for VHL-disease associated RCC: Oral HIF-2α inhibitor — highly targeted, tolerable. For patients with VHL-driven RCC who have not received this agent.[21]
- 05SRS for symptomatic brain mets: Even in hospice-eligible patients, treating a single symptomatic brain met with SRS is a comfort intervention that can prevent neurological decline. Median OS post-SRS for RCC brain mets is 10–14 months in selected patients.[23]
- 06Oligometastatic RCC — metastasectomy: Resection of solitary pulmonary or adrenal met can achieve years of disease-free survival. Worth discussing even at hospice enrollment if patient has limited burden and adequate functional reserve.[19]
- 07Patient goals explicitly include life-prolongation: A well-informed patient who understands prognosis and chooses active treatment should receive it without judgment. RCC is one of the only cancers where a patient on hospice with stable disease might legitimately be de-enrolled to pursue active therapy — the immunotherapy response rates and durability are real. This requires nuanced conversation, not a binary treatment vs hospice framing.
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
RCC is a disease with a history of surprising responses — and that history makes the conversation about stopping treatment uniquely difficult. Patients and families have often been through cycles of progression, new therapy, and unexpected response for years. When you say "there is nothing left to try," they have heard that before and been wrong. Acknowledge that history directly, then be honest about what the current clinical picture actually shows.[26]
- 01IMDC poor-risk with ECOG ≥2: Median OS 5–10 months with treatment. Toxicity from IO/TKI combination often exceeds benefit in poor-risk patients with poor functional status. The toxicity-to-benefit ratio shifts decisively against treatment.[9]
- 02Sarcomatoid differentiation >50%: Median OS <12 months regardless of therapy. IO has modestly improved this, but sarcomatoid-dominant disease remains aggressive and poorly responsive to all available therapies.[11]
- 03Progression through ≥2 IO-containing combinations and ≥2 TKI lines: No established standard-of-care beyond this. Response rates <5–10% in heavily pretreated patients. Clinical trial enrollment is the only evidence-supported option — if unavailable or impractical, further therapy is not expected to provide meaningful benefit.
- 04ECOG ≥3: No evidence of benefit from any systemic therapy for RCC at ECOG ≥3. Performance status is the single strongest predictor of treatment futility.
- 05Uncontrolled brain metastases beyond SRS capacity: Diffuse CNS disease not amenable to focal radiation. WBRT provides limited benefit in RCC brain mets, which are inherently radioresistant to conventional fractionation.[23]
- 06Malignant hypercalcemia refractory to treatment: When calcium cannot be controlled despite aggressive management, median survival is measured in weeks. Refractory hypercalcemia is a terminal event.[3]
- 07Patient goals shift to comfort and presence: When a fully informed patient chooses comfort over treatment — after years of fighting — that clarity deserves the same respect as every treatment decision they made before it. Name the treatment history explicitly: "Everything you tried was real, and it bought you real time. This decision is just as brave."
📋 The unique RCC challenge
RCC patients and families have often been through years of treatment cycles with extraordinary responses followed by progression. The history of "always one more option that worked" makes the conversation about stopping treatment particularly difficult. The hospice clinician must name that history explicitly — acknowledge that the past responses were real — and then be honest about what the current clinical picture means. Do not use generic "there's nothing more we can do" language. Be specific: "The treatments that worked before are no longer working. Your body has told us that. And the options available now carry more risk than benefit based on everything we know about your disease."
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Palliative Radiation for Bone Pain
Grade ASingle fraction 8 Gy to painful bone metastasis
Strong RCT evidence supports single-fraction palliative radiation for painful bone metastases. Equivalent pain relief to multi-fraction regimens with less treatment burden. Highly effective in RCC bone mets. Hospice-compatible — single treatment, same-day. ASTRO evidence-based guideline supports this approach.[24]
SRS for Brain Metastases
Grade ASingle-session SRS, typically 15–24 Gy depending on lesion size
RCC brain mets are radiosensitive to SRS specifically, despite being radioresistant to conventional fractionation. Even in hospice-eligible patients, treating a single symptomatic brain met causing neurological deficits is a legitimate comfort discussion. Median OS post-SRS for RCC brain mets is 10–14 months in selected patients. Can prevent seizure, hemiparesis, or cognitive decline from progressive lesion.[23]
IO Continuation in Early Hospice
Grade BContinue current IO regimen if stable disease at hospice enrollment
RCC is unique in that durable complete responses to IO occur in 8–12% of patients. If a patient is enrolled on hospice while still on IO with stable disease, the conversation about whether to continue is legitimate and worth having with oncology. Not applicable to patients with clear progression, but to those enrolled primarily for performance status and support needs. Requires nuanced goals-of-care conversation.[6]
Renal Artery Embolization
Grade BSelective tumor embolization via interventional radiology
Selective tumor embolization can control catastrophic hemorrhage from primary or metastatic RCC. Hospice-compatible comfort intervention when hemorrhage is the primary symptom driver. Referral to IR before the crisis, not during. Establish the relationship and plan at intake for patients with documented hemorrhage risk.[25]
Acupuncture for Pain, Fatigue & IO-Related Arthralgia
Grade BTwice weekly for 6–8 weeks, then weekly maintenance
Multiple RCTs support acupuncture for cancer-related pain and fatigue. IO-related joint pain specifically may respond to acupuncture — case series in immunotherapy-treated patients show benefit for persistent arthralgia that does not resolve after IO discontinuation. Safe, minimal side effects, well-tolerated in debilitated patients.[27]
MBSR for Long-Trajectory Anxiety
Grade B8-week structured MBSR program; adapted shortened protocols for hospice
Patients with metastatic RCC who have been living with the disease for years develop a specific anticipatory anxiety around scan results and disease changes. MBSR and psycho-oncology support is particularly valuable for this population. RCT evidence in cancer survivors supports reduced distress and improved quality of life. Adapted shorter protocols can be used in hospice setting.[28]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to this diagnosis. Patients will use supplements — this section helps you have the right conversation.
"RCC patients are often the most supplement-savvy patients you'll meet — they've been fighting this disease for years and many have tried everything. The conversation isn't 'stop taking that.' It's 'some of these interact with your medications in ways that can hurt you, and one of them — St. John's Wort — will destroy the blood levels of every TKI your oncologist ever prescribed. Let me help you sort the safe from the dangerous.'"
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Ginger | Grade B | 1 g/day capsule form; ginger tea 2–3 cups/day | Nausea from TKI therapy and systemic disease. Particularly useful for TKI-related GI toxicity which persists even in patients tapering off therapy.[29] | Safe at standard doses. Minimal interactions. Mild antiplatelet effect at very high doses — clinically insignificant at recommended amounts. |
| Melatonin | Grade C | 1–5 mg PO at bedtime | Some anti-tumor signal in RCC preclinically via mTOR pathway modulation. Sleep benefit is real and meaningful given the fatigue burden in RCC.[30] | Safe at standard doses. May complement everolimus pathway effects though clinical evidence limited. Minimal drug interactions. Monitor for morning drowsiness. |
| Astragalus / Huang Qi | Grade C | 500–1000 mg standardized extract BID | Some immune modulation data in RCC patients receiving IFN-alpha historically. General cancer fatigue benefit in Chinese medicine literature. | CYP interactions possible — discuss before using with active IO or TKI therapy. Avoid in patients on immunosuppressants for IO toxicity (corticosteroids). Theoretical immune stimulation concern. |
| Curcumin / Turmeric | Grade C | 500–2000 mg/day standardized curcumin | Anti-inflammatory. mTOR pathway signal in RCC cell lines. May help with IO-related inflammatory symptoms.[31] | ⚠ CYP3A4 interaction with sunitinib, pazopanib, cabozantinib — flag if still on TKI. Antiplatelet caution in hemorrhage-risk patients. RCC is hypervascular — err on the side of caution. |
| Fish Oil / Omega-3 | Grade C | 1–3 g EPA+DHA daily | Cachexia and inflammation. Some anti-tumor signal in RCC. Anti-inflammatory properties may help with IO-related joint pain. | ⚠ Caution in patients with active hemorrhage risk — antiplatelet effect. RCC is one of the most hemorrhage-prone cancers. Standard doses generally safe; high doses (>3 g/day) increase bleeding risk. |
🚫 Avoid in This Diagnosis
- St. John's Wort: CYP3A4 inducer — destroys sunitinib, pazopanib, cabozantinib, axitinib, and everolimus blood levels. This is the most critical herb-drug interaction in RCC. Even patients recently discontinued from TKI should avoid — drug interactions persist beyond drug half-life. This single supplement can render an active treatment completely ineffective.[32]
- High-dose fish oil, Ginkgo, Vitamin E (>400 IU/day): Antiplatelet effects compound hemorrhage risk. RCC is one of the most hemorrhage-prone cancers due to hypervascular tumor biology. Anything that impairs hemostasis is particularly dangerous in this population.
- Echinacea and immunostimulant herbs (Cat's Claw, Astragalus at high doses, Reishi at immunostimulant doses): Theoretical immune activation may worsen IO-related immune toxicities — colitis, pneumonitis, hepatitis — which can be severe and life-threatening. Avoid in patients who have received or are receiving IO therapy. Immune toxicities persist months to years after IO discontinuation.[12]
- High-dose Vitamin C IV: Theoretical interference with IO mechanism. Limited but legitimate concern given overlapping oxidative pathways. Avoid during active IO therapy.
- Any herb with nephrotoxic potential in single-kidney patients: Aristolochic acid (found in some Chinese herbal preparations), chromium, germanium — renal toxicity risk amplified in patients with only one kidney post-nephrectomy. Verify kidney count before approving any supplement with renal clearance or nephrotoxic potential.
Timeline Guide
A guide, not a prediction. Every patient's trajectory is shaped by histology, molecular profile, treatment response, and comorbidities.
RCC has the most unpredictable trajectory of any cancer on this list. IMDC risk classification, histologic subtype, sarcomatoid component, prior treatment responses, and immunotherapy durability all dramatically alter the timeline. A favorable-risk clear cell patient on first-line IO/TKI may be years from hospice. A poor-risk sarcomatoid patient may be weeks. Use this guide as a framework, not a script — and update your prognosis at every visit based on functional trajectory, not imaging alone.[9]
YRS–
MOS
MOS
Stable / Responding Disease — The Long Phase
- Localized RCC post-nephrectomy — surveillance with CT every 6 months; functionally well; may never recur (Stage I 5-year recurrence <10%)[7]
- Or: metastatic on IO/TKI combination with favorable-risk disease achieving partial or complete response — this phase can last years
- This is where RCC differs from every other cancer on this list: a patient in this phase looks well, feels reasonably well, and may be confused about why hospice or palliative care is relevant
- Palliative care integration is almost never offered at this stage and should be — advance care planning, goals conversations, managing TKI side effects (hypertension, diarrhea, fatigue, hand-foot syndrome), and psychosocial support for living with metastatic disease[33]
- Paraneoplastic syndromes may already be present — hypercalcemia, polycythemia, paraneoplastic fever — monitor and manage
MOS–
1 YR
1 YR
First Progression — The Missed Window
- First progression on IO/TKI — second-line therapy initiated (cabozantinib, nivolumab monotherapy, lenvatinib + everolimus)
- Performance status still ECOG 1–2; fatigue, pain, and IO-related toxicities accumulating
- Paraneoplastic syndromes possibly present or worsening — hypercalcemia causing confusion, polycythemia causing headaches and hypertension
- Bone and brain metastases developing or progressing — new pain sites, neurological symptoms
- This is the window for palliative integration and it is almost universally missed in RCC because patients "look too good"[33]
- IO immune toxicity from first-line may still be active — colitis, pneumonitis, hypothyroidism, nephritis — manage alongside disease progression
WKS–
MOS
MOS
Hospice Transition — The Right Time
- Progression through multiple lines of therapy — ECOG declining to 2–3
- Bone pain requiring regular opioids; brain mets managed with SRS or untreatable
- Hemorrhage risk increasing as tumor progresses — document vascular tumor burden and prepare
- Paraneoplastic syndromes worsening — refractory hypercalcemia, persistent fever, worsening polycythemia
- Hospice transition window — this is the correct enrollment point. Comfort kit, hemorrhage protocol, family education, medication reconciliation[26]
- Steroid taper management if ongoing IO toxicity; denosumab continuation for bone mets
DAYS–
WKS
WKS
Active Dying — Pre-Active Phase
- Bed-bound; hemorrhage risk highest — prepare family with specific instructions
- Paraneoplastic fever possibly ongoing — do not start antibiotics without clear infectious source; NSAIDs or dexamethasone
- Bone pain requiring around-the-clock opioids — convert to SQ medications as oral route fails
- Brain met neurological deficits may dominate clinical picture — seizure precautions if cortical involvement
- Renal function declining, especially if single kidney — adjust renally-cleared medications; morphine metabolites accumulate in renal failure (consider hydromorphone rotation)
- Family education: hemorrhage protocol reviewed, midazolam at bedside, dark towels available
HRS–
DAYS
DAYS
Final Hours
- Possible hemorrhage if highly vascular tumor — have midazolam drawn and at bedside; dark cloths visible
- Cheyne-Stokes breathing; mottling of knees and feet; mandibular breathing
- Unresponsive or minimally responsive — auditory awareness may persist; speak to them, not about them
- Glycopyrrolate for terminal secretions if present; continue opioid infusion for comfort
- Family presence is the clinical priority — the years of fighting are over; this is the moment of presence
Medications to Anticipate
Symptom-targeted pharmacology for this diagnosis. What to have in the comfort kit, what to titrate first, and what the evidence supports.
Pain and paraneoplastic syndromes are the dominant drivers of medication decisions in end-stage RCC. Bone metastases — osteolytic and fracture-prone — are the most common source of severe pain. Paraneoplastic hypercalcemia, fever, and polycythemia require targeted interventions distinct from metastatic symptom management. IO immune toxicity management (corticosteroid tapers) is frequently a primary clinical task at hospice enrollment.[12][3]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Morphine or Oxycodone | Opioid / Bone met pain, tumor invasion | Morphine 2.5–5 mg PO q4h; or Oxycodone 2.5–5 mg PO q4h | First-line for bone met and tumor pain. SQ conversion as oral route fails. ⚠ Avoid NSAIDs if single kidney or renal impairment. GFR-dependent dose adjustment for morphine — metabolites (M3G, M6G) accumulate in renal failure; consider hydromorphone rotation if GFR <30.[34] |
| Gabapentin or Pregabalin | Anticonvulsant / Neuropathic bone pain, IO-related neuropathy | Gabapentin 300 mg TID, titrate to 900 mg TID; or Pregabalin 75 mg BID | Common late toxicity from prior TKI and IO therapy. Effective for neuropathic bone pain component. Reduce dose in renal impairment. Monitor for sedation — additive with opioids. |
| Dexamethasone | Corticosteroid / Brain edema, paraneoplastic fever, bone pain adjunct | 4–8 mg PO/IV BID for brain mets; 2–4 mg daily for other indications | Brain mets edema — essential for symptomatic control. Paraneoplastic fever — partial suppression. Bone met pain adjunct. Appetite stimulation. Monitor glucose closely.[35] |
| Denosumab | RANKL inhibitor / Bone met fracture prevention | 120 mg SQ q4 weeks | Preferred over zoledronic acid in RCC — does not require renal dose adjustment. Most RCC patients have renal impairment from nephrectomy, prior TKI nephrotoxicity, or obstruction. Fracture prevention is comfort care. Monitor calcium — hypocalcemia risk.[22] |
| Midazolam | Benzodiazepine / Hemorrhage emergency, terminal agitation | 5–10 mg SQ immediately for catastrophic bleeding; 2.5–5 mg SQ PRN for agitation | ⚠ MUST be drawn, labeled, and at bedside if documented hemorrhage risk. RCC is highly vascular — catastrophic hemorrhage from tumor erosion or renal bed is a documented clinical risk. Also for terminal agitation. |
| Prednisone or Dexamethasone | Corticosteroid / IO immune toxicity management | Prednisone 1–2 mg/kg/day for active IO toxicity; taper over 4–8+ weeks | If patient arrives on hospice with ongoing IO toxicity (colitis, pneumonitis, hepatitis, nephritis), corticosteroid taper management becomes a primary clinical task. ⚠ Do not abruptly discontinue. Most IO toxicities require weeks to months of steroid taper.[12] |
| Haloperidol | Antipsychotic / Nausea (paraneoplastic and opioid-induced) | 0.5–1 mg PO/SQ q8h | First-line for opioid-induced and metabolic nausea in hospice. Effective for paraneoplastic nausea. SQ route available when oral fails. |
| Ondansetron | 5-HT3 antagonist / Nausea adjunct | 4–8 mg PO/SQ q8h | Adjunct for nausea not controlled with haloperidol alone. Constipating — ensure bowel regimen in place. |
| Indomethacin or Naproxen | NSAID / Paraneoplastic fever | Indomethacin 25 mg PO TID; or Naproxen 250–500 mg PO BID | First-line for RCC-associated paraneoplastic fever. ⚠ Caution in renal impairment — if GFR <30, use acetaminophen 1g q6h + dexamethasone instead. Do not prescribe antibiotics for paraneoplastic fever.[3] |
| Lorazepam | Benzodiazepine / Anxiety | 0.5–1 mg PO/SQ q4–6h PRN | Adjunctive for anxiety. Useful for anticipatory nausea and scan-anxiety patterns that persist into hospice. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h | Reduces secretions without CNS effects. Preferred over hyoscine in conscious patients. |
🚨 Comfort Kit Must-Haves: Hemorrhage Protocol
RCC is a hypervascular tumor. Hemorrhage — from the primary tumor bed, from vascular bone mets, or from metastatic lesions adjacent to major vessels — is a documented risk. For any patient with known vascular tumor burden, prior hemorrhagic events, or large primary tumor remnant:
- Midazolam 5–10 mg SQ must be drawn, labeled, and at the bedside
- Dark cloths or towels must be visible and accessible (not white — blood on white fabric amplifies family trauma)
- Family briefed on exactly what to do: stay present, administer midazolam if instructed, call the nurse, do not call 911
- Write the protocol in the care plan and review it at every visit
- The goal is not to prevent the event — it is to ensure that if it happens, the family is prepared, the patient is sedated quickly, and the moment is not traumatic
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.
1
Paraneoplastic syndromes require a different clinical framework
Paraneoplastic syndromes are clinical problems caused by the tumor, not by tumor bulk — they require a different clinical framework than metastatic symptoms. The four most common in RCC: Hypercalcemia of malignancy (PTHrP-mediated — causes confusion, nausea, constipation, polyuria; assess calcium when the clinical picture doesn't add up); Polycythemia (erythropoietin-secreting tumor — causes hyperviscosity, headache, hypertension, thrombosis risk); Paraneoplastic fever (TNF and IL-6 mediated — can be high and persistent; responds to NSAIDs or dexamethasone, not antibiotics; do not prescribe antibiotics for paraneoplastic fever without ruling out infection); Hypertension (renin-secreting tumor — distinct from TKI-related hypertension; persists until nephrectomy if not performed).[3]
2
IO immune toxicity does not end when IO ends
Patients arriving on hospice who received nivolumab, pembrolizumab, or ipilimumab within the past year may have ongoing or re-activated immune colitis, pneumonitis, hepatitis, or nephritis. If a hospice patient has unexplained diarrhea, dyspnea, elevated LFTs, or rising creatinine — consider IO toxicity before attributing to disease progression. High-dose corticosteroids (prednisone 1–2 mg/kg/day) are the treatment. Do not abruptly discontinue steroids — taper over 4–8 weeks minimum. Some IO toxicities (endocrinopathies like hypothyroidism and adrenal insufficiency) are permanent and require lifelong replacement.[12]
3
RCC bone mets are lytic and fracture-prone
Unlike prostate cancer's osteoblastic lesions, RCC creates lytic holes in bone. Pathologic fracture risk is high and often underestimated. Know the bone met locations and load from imaging. Any weight-bearing bone met in the femur or humerus deserves a fracture risk conversation. Prophylactic fixation may be appropriate even in hospice patients if expected survival is >3 months and fracture would cause catastrophic functional loss. Denosumab over zoledronic acid — does not require renal dose adjustment.[22][13]
4
The trajectory is genuinely unpredictable — update prognosis at every visit
Do not anchor too hard on IMDC risk alone. Some poor-risk patients stabilize on IO. Some favorable-risk patients deteriorate rapidly from hemorrhage or paraneoplastic crisis. RCC has humbled every prognostic tool ever applied to it. Use functional trajectory — what the patient can do this week versus last week — as your primary prognostic instrument. Performance status trend over 2–4 weeks is more accurate than any biomarker or risk score.[9]
5
Hemorrhage preparedness is non-negotiable in RCC
The tumor is hypervascular. Have the hemorrhage protocol written, reviewed, and understood before you leave the intake visit. Midazolam drawn and labeled at the bedside. Dark towels accessible. Family briefed on what hemorrhage looks like and exactly what to do. A family who was prepared for a hemorrhage event is shaken but not traumatized. A family who was not prepared is traumatized in a way that affects their grief for years. This is preventable harm — prevent it.[25]
Clinical Pearl
"Paraneoplastic fever in RCC is not sepsis. Before you prescribe antibiotics for a patient with persistent high fever and no obvious source, ask when the fever started relative to disease progression. If the answer is 'about when the tumor grew,' the fever is the tumor. NSAIDs or dexamethasone. Not vancomycin."
"I had a patient — stage IV clear cell, IMDC intermediate, bone mets everywhere — spiking fevers of 103 every afternoon for weeks. On-call doc ordered blood cultures and levofloxacin three times. Cultures were always negative. I finally checked a CRP, sent it to oncology, and they said 'that's paraneoplastic — indomethacin.' Fever broke in 24 hours. Three rounds of unnecessary antibiotics because nobody thought to ask whether the tumor itself was the source. Know the paraneoplastic syndromes. They will fool you every time."
— Waldo, NP · Terminal2
Psychosocial & Spiritual Care
Existential distress, depression screening, spiritual assessment, and goals-of-care communication. The symptom burden you can't see on a vitals sheet.
Psychosocial distress in metastatic RCC has a character distinct from nearly every other cancer in hospice. These patients have often been living with metastatic disease for 3, 5, or even 7 years. They have watched treatments work, stop working, be replaced, and fail again. By the time they arrive at hospice, they may be exhausted in a way that newly diagnosed patients are not — and the emotional tools that work for newly diagnosed patients do not work here. The clinician must recognize this and adjust.[33]
Your job is not to provide the answers. Your job is to ask the questions that make space for the patient's own answers to emerge — and to connect them with the right people when they need more than you can offer.
Psychological Distress Screening
Depression — Screen Every Patient
Grade BSingle-question screen: "Are you depressed?" has 100% sensitivity in terminally ill populations when phrased directly.
- PHQ-2: "Little interest/pleasure" + "Feeling down/hopeless" — score ≥3 warrants full PHQ-9
- Mirtazapine 7.5 mg QHS: First-line in hospice — addresses depression, insomnia, and anorexia simultaneously. Faster onset than SSRIs.
- Distinguish depression from appropriate sadness — both deserve attention; only one warrants pharmacotherapy
- RCC-specific: Depression in long-trajectory patients often presents as resignation rather than sadness — "I'm just tired of all this" may be depression, not acceptance
Anxiety & Scan-Culture Residue
Grade B- Scan anxiety: RCC patients who have been in active treatment live scan-to-scan — every 8–12 weeks their fate is determined by a radiology report. This creates a specific chronic anxiety that does not resolve when treatment stops. The absence of surveillance scans in hospice can be experienced as both relief and terror. Address it explicitly.
- Lorazepam 0.5 mg PRN for acute anxiety episodes. Dignity therapy for existential distress.
- Refer to social work and chaplain at enrollment — not at crisis
RCC-Specific Psychosocial Dimensions
1
The long-trajectory grief
RCC patients may have been living with metastatic disease for years. They have watched treatments work, stop working, be replaced, and fail again. By the time they arrive at hospice they may be exhausted in a way that newly diagnosed patients are not. Acknowledge this explicitly: "You've been fighting this for a long time. We see that. We honor that. And we're going to take care of you now."
2
The "one more thing that might work" psychology
RCC has an unusually rich treatment pipeline and a history of surprising responses. Patients and families often find it psychologically impossible to accept that no further options exist because that has been wrong before. Name this directly and compassionately: "I know you've been told before that there was nothing left, and then there was. I understand why it's hard to believe this time is different. But your body is telling us something now, and I want to be honest with you about what I see."
3
IO toxicity grief
Patients who had to discontinue immunotherapy because of severe immune toxicity often feel that the treatment that was working was taken away. This is a specific and painful loss — the treatment didn't fail; their body couldn't tolerate it. Acknowledge it: "The immune therapy was working. Your body reacted to it in a way that made it unsafe to continue. That's not your fault, and I know it's painful."
4
Paraneoplastic fever and caregiver confusion
Persistent high fever in a patient with RCC without an obvious infection source is deeply alarming to families who interpret it as sepsis or suffering. Explain paraneoplastic fever clinically and in plain language before it becomes a crisis. Families who understand what is causing the fever are less likely to call 911.
Spiritual Assessment
Use the FICA framework: Faith/beliefs, Importance, Community, Address. Ask: "What gives you strength during this time?" This opens spiritual conversation without assuming any tradition. For RCC patients specifically, the spiritual question is often about meaning after years of fighting: "Was it worth it? Did I make the right choices?" Create space for that question without rushing to answer it.
Goals-of-Care Communication
RCC-Specific Goals Framing
- "Not dying in a hospital on a clinical trial" — this is the most common operative goal when you ask directly. The RCC journey often ends with aggressive trial enrollment. Name the alternative explicitly.
- "What do you want the rest of this time to look like?" — opens a conversation about home, comfort, and presence
- Build the plan around what the patient is choosing, not what they are giving up
- For patients who have been in active treatment for years, the shift to hospice may feel like a loss of identity — "I've been a cancer fighter for five years. Who am I now?" Address this.
Communication Pitfalls
- Don't say "there's nothing more we can do": RCC patients have heard this before and been wrong. Be specific about what has changed clinically.
- Don't minimize the treatment history: Every treatment they received was real and bought real time. Acknowledge it explicitly.
- Don't conflate hospice with giving up: Frame around what hospice adds — pain control, symptom management, presence, family support
- Don't have this conversation standing up: Sit down. Make eye contact. Leave silence.
Suicidal Ideation & Hastened Death Requests
Passive wish for death ("I'm ready to go") is common in long-trajectory patients and often existentially appropriate. Assessment requires careful distinction: passive wish for death (common, often appropriate), active suicidal ideation with plan (requires immediate psychiatric engagement), and medical aid in dying requests (legal in some jurisdictions — requires specific protocol). Do not conflate these. Do not avoid the question.
"The hardest RCC patients aren't the ones who are angry. They're the ones who are quiet. They've been fighting for years. They're tired in a way that goes past the body. They've already processed more loss than most people face in a lifetime — loss of a kidney, loss of treatments that worked, loss of the future they planned. When they say 'I'm ready,' believe them. And then make the remaining time matter."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
Your loved one has been living with kidney cancer for what may feel like a very long time. You have been there through surgeries, treatments, side effects, and scan results — and you have watched them fight with everything they had. What you are doing now — choosing to focus on comfort, presence, and quality time — is not giving up on that fight. It is the next chapter of it. This guide will help you understand what to expect and how you can help.
What You May See
- Severe fatigue: RCC-related fatigue is one of the most profound in all of oncology. Sleeping most of the day is expected and normal. This is the disease and years of treatment taking their toll — it is not laziness or depression.
- Bone pain: Especially in the back, hips, or limbs where cancer has spread. This is manageable with medication. Do not wait to report uncontrolled pain — the team has strong medications specifically for this.
- High fever without obvious infection: Paraneoplastic fever — the tumor itself is causing this, not an infection. Your nurse will explain. It is treated with anti-inflammatory medication, not antibiotics. It may come and go. It looks alarming but it is manageable.
- Confusion or personality change: Possibly from high calcium levels in the blood (a common complication of kidney cancer) or from cancer that has spread to the brain. Call the nurse if this is new or worsening — these are treatable symptoms.
- Bleeding: Kidney cancer tumors have many blood vessels. Bleeding from the tumor site or in the urine can occur. Call the nurse immediately if you see significant bleeding. Stay calm, stay present, and follow the plan your nurse has reviewed with you.
- Headaches or vision changes: May indicate brain involvement. Report to your nurse immediately. Treatment may be available even now to help with these symptoms.
How You Can Help
- Do not push food: Appetite loss is expected and normal at this stage. Small offerings of favorite soft foods and sips of preferred drinks are enough. Forcing food causes nausea and suffering, not strength.
- Report new or worsening bone pain immediately: Fracture risk is real in kidney cancer that has spread to the bones. Early reporting prevents a crisis. If your loved one suddenly cannot bear weight on a leg, call the nurse immediately.
- Take the fever seriously but do not panic: Your nurse will tell you which temperatures to call about and which are expected from the disease itself. Write these numbers down and keep them visible.
- If bleeding occurs: Stay calm. Stay present. Apply gentle pressure if the bleeding is external and accessible. Call the nurse immediately. If your nurse has provided emergency medication (midazolam) and instructed you on how to give it, follow those instructions. Do not call 911 unless your nurse has told you to.
- Keep the environment safe: If balance or strength is affected by bone mets or brain involvement, remove fall hazards, consider a hospital bed with rails, and keep pathways clear.
- Be present: Your loved one has been fighting this disease for a long time. What they need most now is you, not a treatment. Sitting quietly, holding a hand, reading aloud — these are not small things. They are the most important things.
📞 Call the nurse immediately if you see:
Significant bleeding that does not slow — call the nurse immediately. If your nurse has provided emergency medication and you have been instructed on its use, administer it. Stay with your loved one. • Sudden severe headache unlike any prior headache — possible brain hemorrhage. Call the nurse. • New confusion or seizure — call the nurse immediately. Move objects away from the person, do not restrain, time the seizure if possible. • Inability to be woken — this may be expected at certain stages; your nurse will tell you when. If unexpected, call. • Sudden severe bone pain with inability to bear weight — possible fracture. Call the nurse. Do not attempt to move the affected limb.
🙏 You have been on this journey for a long time. Longer than most cancer families. You have watched treatments work, stop working, and be replaced. You have held hope and had it shaken, held it again, and had it shaken again. What you are doing now — choosing presence over pursuit, home over hospital — is not giving up. It is wisdom. It is love made practical. The data is clear: patients who have people present do better — not just emotionally, but clinically. You are part of this care team. You always have been.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01Paraneoplastic syndromes are clinical problems separate from tumor burden — and they will fool you if you don't know them. The four in RCC: hypercalcemia, polycythemia, paraneoplastic fever, and hypertension. When your RCC patient has a symptom that doesn't fit the metastatic pattern — confusion without brain mets, headache without a reason, fever without a source, hypertension in someone who was never hypertensive — think paraneoplastic before thinking disease progression. Check a calcium, a CBC, and a renin level. The tumor itself is producing substances that are causing clinical problems in organs it has never touched. That's the part that catches clinicians off guard. Know it before you walk in the door.
- 02Paraneoplastic fever is not sepsis. I cannot say this loudly enough. If your RCC patient has a persistent high fever — 102, 103, coming every afternoon like clockwork — and blood cultures are negative, and the chest X-ray is clear, and the UA is clean, stop ordering antibiotics. The tumor is producing TNF and IL-6. It is causing the fever. NSAIDs are first-line — indomethacin 25 mg TID will often break the cycle within 24 hours. If kidneys can't handle NSAIDs, use dexamethasone. Say it out loud to the family: "This fever is coming from the tumor, not from an infection. We know what's causing it and we're treating it directly." That sentence prevents a 911 call at 2 AM.
- 03IO immune toxicity does not end when IO ends. This catches everyone. Patient stopped nivolumab six months ago, arrives on hospice, and three weeks in develops profuse watery diarrhea. The instinct is to call it disease progression or a GI bug. It's not. It's immune-mediated colitis reactivating. Nivolumab, pembrolizumab, ipilimumab — these agents rewire the immune system permanently. Colitis, pneumonitis, hepatitis, nephritis — any of these can flare months or years after the last dose. If your hospice patient has unexplained diarrhea, new dyspnea, elevated LFTs, or rising creatinine, think IO toxicity first. The treatment is high-dose corticosteroids, and the earlier you start, the better the response.
- 04Hemorrhage preparedness is non-negotiable. RCC is hypervascular. The tumors look like blood-filled sponges on imaging, and they can erode into the renal artery, into adjacent vessels, or bleed from bone mets that have eaten through cortical bone. Write the hemorrhage protocol at intake. Have midazolam 5–10 mg drawn, labeled, and at the bedside. Dark towels — not white — visible and accessible. Review the protocol with the family, nurse, and aide at every visit. A family who was prepared for a hemorrhage event is shaken but intact. A family who was not is traumatized in a way that complicates their grief for years. That is preventable harm. Prevent it.
- 05RCC bone mets are lytic, not sclerotic. They punch holes in bone. This isn't prostate cancer where the bone gets harder — this is the opposite. The tumor eats through cortical bone and leaves behind a structure that can fracture under normal body weight. I've seen femoral fractures from standing up. Know where the bone mets are — every one of them. Know which ones are in weight-bearing bones. Have the fracture conversation with the family before it happens: "There are areas of weakness in the bone. We need to be careful about weight-bearing." Denosumab for fracture prevention is comfort care. Start it or continue it.
- 06The trajectory is genuinely unpredictable, and you need to be honest about that — with yourself and with the family. I've written "prognosis: weeks" on intake assessments for RCC patients who were still alive eight months later because their immune system decided to fight the tumor one more time. I've also written "prognosis: months" for patients who bled out from a bone met two weeks later. IMDC risk scores are useful population-level tools. They are terrible at predicting what happens to the person in front of you. Update your prognosis at every visit based on what you see, not what the chart says. Functional trajectory — what they can do this week versus last week — is your best instrument.
- 07The "one more option" conversation is the hardest conversation in RCC. Harder than any other cancer. Because in RCC, there often was one more option. And it often worked. For years. So when you say "we've run out of effective options," the patient and family have a legitimate reason to not believe you — because the last three doctors who said that were wrong. Acknowledge that directly: "I know you've been told this before and it wasn't true. I understand why this is hard to believe. But what I'm seeing now in your body — the functional decline, the pain pattern, the labs — is telling me something different than before." Then be quiet and let them process.
- 08IO-related arthralgia is undertreated in RCC hospice patients. These patients arrive with joint pain and myalgia that they've been told is "just the cancer." It's not — or at least, not all of it. Immune checkpoint inhibitors cause an inflammatory arthritis that persists for months to years after discontinuation. It looks like RA on exam — symmetric small joint swelling, morning stiffness, elevated inflammatory markers. It responds to low-dose prednisone (5–10 mg daily) and acupuncture. Don't attribute everything to disease progression. Take a careful joint exam and ask about the temporal relationship to IO therapy. Treating this correctly can significantly improve quality of life with minimal intervention.
- 09Denosumab over zoledronic acid in bone-dominant RCC. Every time. Denosumab does not require renal dose adjustment. Most of your RCC patients have some degree of renal impairment — from nephrectomy (they're working with one kidney), from prior TKI nephrotoxicity (sunitinib, pazopanib, cabozantinib all hit the kidneys), or from obstructive uropathy. Zoledronic acid requires GFR >35 mL/min, and half your patients won't meet that threshold. Denosumab 120 mg SQ q4 weeks — it works, it prevents fractures, and it doesn't care about the creatinine. Default to it for every bone-modifying therapy conversation in RCC.
- 10Caregiver depletion in RCC is unlike any other diagnosis you'll see. These families have often been caregiving for years — not weeks, not months, years. Through surgeries, through first-line therapy and its side effects, through progression, through second-line, through clinical trials, through brain radiation. By the time they reach hospice, the caregiver is already running on fumes. Assess caregiver capacity not once at enrollment, but at every visit. Ask them directly: "How are you holding up? Not fine — how are you really doing?" Connect them to respite care, to social work, to caregiver support groups before the collapse, not after. The caregiver who burns out is the caregiver who calls 911 at 3 AM because they can't cope — and that call undoes the plan you've built. Prevention is the intervention.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.
2
Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs — Part A: Renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93-105.
3
Sacco E, Pinto F, Sasso F, et al. Paraneoplastic syndromes in patients with urological malignancies. Urol Int. 2009;83(1):1-11.
4
Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (KEYNOTE-426). N Engl J Med. 2019;380(12):1116-1127.
5
Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma (CheckMate 9ER). N Engl J Med. 2021;384(9):829-841.
6
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma (CheckMate 214). N Engl J Med. 2018;378(14):1277-1290.
7
Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82(4):399-410.
8
Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(1):71-90.
9
Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-5799.
10
Shetty A, Youngblood RM, Beckermann KE, et al. Renal medullary carcinoma: a case series and review of the literature. Kidney Cancer. 2021;5(2):71-80.
11
Rini BI, Motzer RJ, Powles T, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404-2415.
12
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-1768.
13
Woodward E, Jagdev S, McParland L, et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 2011;48(1):160-166.
14
Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74-84.
15
Karami S, Boffetta P, Rothman N, et al. Renal cell carcinoma, occupational pesticide exposure and modification by glutathione S-transferase polymorphisms. Carcinogenesis. 2008;29(8):1567-1571.
16
Maher ER, Neumann HP, Richard S. Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19(6):617-623.
17
Rose TL, Kim WY. Renal cell carcinoma: racial and ethnic disparities in incidence, clinical characteristics, and survival. Urol Oncol. 2020;38(6):602-609.
18
Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma (CARMENA). N Engl J Med. 2018;379(5):417-427.
19
Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873-2882.
20
Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma (METEOR). N Engl J Med. 2015;373(19):1814-1823.
21
Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385(22):2036-2046.
22
Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082-3092.
23
Kotecha R, Tonse R, Gong Y, et al. Stereotactic radiosurgery for brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2020;108(5):1178-1186.
24
Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965-976.
25
Schwartz MJ, Smith EB, Trost DW, Vaughan ED Jr. Renal artery embolization: clinical indications and experience from over 100 cases. BJU Int. 2007;99(4):881-886.
26
Lam DY, Scherer JS, Brown M, et al. A qualitative study of early integrated palliative care in metastatic renal cell carcinoma. J Palliat Med. 2021;24(6):861-868.
27
Hershman DL, Unger JM, Greenlee H, et al. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer. JAMA. 2018;320(2):167-176.
28
Carlson LE, Doll R, Stephen J, et al. Randomized controlled trial of Mindfulness-Based Cancer Recovery versus Supportive Expressive Group Therapy for distressed survivors of breast cancer (MINDSET). J Clin Oncol. 2013;31(25):3119-3126.
29
Marx W, Ried K, McCarthy AL, et al. Ginger — mechanism of action in chemotherapy-induced nausea and vomiting: a review. Crit Rev Food Sci Nutr. 2017;57(1):141-146.
30
Reiter RJ, Rosales-Corral SA, Tan DX, et al. Melatonin, a full-service anti-cancer agent: inhibition of initiation, progression and metastasis. Int J Mol Sci. 2017;18(4):843.
31
Bimonte S, Barbieri A, Leongito M, et al. Curcumin anticancer studies in pancreatic cancer. Nutrients. 2016;8(7):433.
32
Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94(16):1247-1249.
33
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742.
34
Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58-e68.
35
Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):103-114.
36
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (RECORD-1). Lancet. 2008;372(9637):449-456.
37
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124.
38
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134.
39
Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-1068.
40
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma (CheckMate 025). N Engl J Med. 2015;373(19):1803-1813.
41
Chochinov HM, Hack T, Hassard T, et al. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol. 2005;23(24):5520-5525.
42
Gold KA, Wirth LJ, Chin K, et al. Von Hippel-Lindau disease: an update on the diagnosis and management of hemangioblastoma and renal cell carcinoma. J Intern Med. 2022;291(2):149-163.
43
Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk (CABOSUN). J Clin Oncol. 2017;35(6):591-597.
44
Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (JAVELIN Renal 101). N Engl J Med. 2019;380(12):1103-1115.
45
Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261-2266.
46
Hui D, Bruera E. The Edmonton Symptom Assessment System 25 years after: past, present, and future developments. J Pain Symptom Manage. 2017;53(3):630-643.
47
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC). J Immunother Cancer. 2017;5(1):95.
48
Motzer RJ, Jonasch E, Boyle S, et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2023. J Natl Compr Canc Netw. 2023;21(1):9-20.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.